Literature DB >> 23891256

Influence of comorbidities on the phenotype of patients affected by Charcot-Marie-Tooth neuropathy type 1A.

Giulia Ursino1, M Antonia Alberti, Marina Grandis, Lizia Reni, Davide Pareyson, Emilia Bellone, Chiara Gemelli, Mario Sabatelli, Chiara Pisciotta, Marco Luigetti, Lucio Santoro, Laura Massollo, Angelo Schenone.   

Abstract

Charcot-Marie-Tooth type 1A (CMT1A) is the most common inherited neuropathy. The phenotype of patients affected by CMT1A is highly variable and may be influenced by several conditions. We evaluated how comorbidities such as diabetes, hypothyroidism, exposure to toxins and obesity can modify or exacerbate the clinical and neurophysiological phenotype of CMT1A patients. Disability was measured using the classic CMT neuropathy score. Compared to controls, all groups of CMT1A patients with comorbidities had higher CMT neuropathy score. In particular, patients with CMT1A and diabetes mellitus show motor subscores which are significantly higher than in control CMT1A. Amplitudes of ulnar CMAP are lower in patients with CMT1A and diabetes mellitus, but not at a significant level. As expected, motor nerve conduction velocity is not influenced by any of the comorbidities. The presence of concomitant diseases shows a tendency to worsen the clinical and neurophysiological CMT1A phenotype, especially in patients with CMT1A and diabetes mellitus, where higher values in the CMT neuropathy score and clinical motor subscore have been observed.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CMT; CMT1A; Diabetes; Hypothyroidism; Obesity; Phenotype; Toxic

Mesh:

Substances:

Year:  2013        PMID: 23891256     DOI: 10.1016/j.nmd.2013.07.002

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  7 in total

1.  Characteristics of demyelinating Charcot-Marie-Tooth disease with concurrent diabetes mellitus.

Authors:  Zhiliang Yu; Xiaohua Wu; Huijun Xie; Ying Han; Yangtai Guan; Yong Qin; Huimin Zheng; Jianming Jiang; Zhenmin Niu
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

2.  Charcot-Marie-Tooth Disease Type 1A: Influence of Body Mass Index on Nerve Conduction Studies and on the Charcot-Marie-Tooth Examination Score.

Authors:  Nivedita U Jerath; Michael E Shy
Journal:  J Clin Neurophysiol       Date:  2017-11       Impact factor: 2.177

Review 3.  New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain.

Authors:  Eva L Feldman; Klaus-Armin Nave; Troels S Jensen; David L H Bennett
Journal:  Neuron       Date:  2017-03-22       Impact factor: 17.173

4.  Association Between Body Mass Index and Disability in Children With Charcot-Marie-Tooth Disease.

Authors:  Gabrielle A Donlevy; Sarah P Garnett; Kayla M D Cornett; Marnee J McKay; Jennifer N Baldwin; Rosemary R Shy; Sabrina W Yum; Timothy Estilow; Isabella Moroni; Maria Foscan; Emanuela Pagliano; Davide Pareyson; Matilde Laura; Trupti Bhandari; Francesco Muntoni; Mary M Reilly; Richard S Finkel; Janet E Sowden; Katy J Eichinger; David N Herrmann; Michael E Shy; Joshua Burns; Manoj P Menezes
Journal:  Neurology       Date:  2021-09-07       Impact factor: 9.910

5.  A case report of hereditary neuropathy with liability to pressure palsies accompanied by type 2 diabetes mellitus and psoriasis.

Authors:  Jing Li; Bing Niu; Xiaoling Wang; Huaiqiang Hu; Bingzhen Cao
Journal:  Medicine (Baltimore)       Date:  2017-05       Impact factor: 1.889

Review 6.  The genetics of Charcot-Marie-Tooth disease: current trends and future implications for diagnosis and management.

Authors:  J Chad Hoyle; Michael C Isfort; Jennifer Roggenbuck; W David Arnold
Journal:  Appl Clin Genet       Date:  2015-10-19

Review 7.  PMP22 related neuropathies: Charcot-Marie-Tooth disease type 1A and Hereditary Neuropathy with liability to Pressure Palsies.

Authors:  Barbara W van Paassen; Anneke J van der Kooi; Karin Y van Spaendonck-Zwarts; Camiel Verhamme; Frank Baas; Marianne de Visser
Journal:  Orphanet J Rare Dis       Date:  2014-03-19       Impact factor: 4.123

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.